-
Transl Lung Cancer Res: The efficacy of pembrolizumab (pembrolizumab) alone or in combination in the treatment of patients with advanced non-small cell lung cancer with bone metastases
Time of Update: 2022-03-04
30-40% of Shanghai Chest Hospital affiliated to Shanghai Jiaotong University and multi-center conducted a retrospective study to evaluate the efficacy of pembrolizumab (pembrolizumab) alone or in combination in the treatment of patients with advanced non-small cell lung cancer with bone metastases .
-
JCO: H1-antihistamines reduce the risk of hepatocellular carcinoma in patients with HBV, HCV or HBV-HCV co-infection
Time of Update: 2022-03-04
published a study in the Journal of Clinical Oncology, which investigated the correlation between the use of AH and the risk of hepatocellular carcinoma (HCC) in patients with HBV, HCV or HBV-HCV co- infection [4] .
-
Ann Oncol: Phase II clinical study ROAR update: the efficacy of Dabrafenib (dabrafenib) combined with trametinib (trametinib) in the treatment of BRAF V600E mutant anaplastic thyroid cancer
Time of Update: 2022-03-04
The updated data from the ROAR study further confirmed the efficacy of dabrafenib + trametinib in the treatment of BRAF V600E-mutated anaplastic thyroid cancer (ATC) .
The updated data from the ROAR study further confirmed the efficacy of dabrafenib + trametinib in the treatment of BRAF V600E-mutated anaplastic thyroid cancer (ATC) .
-
Cancer Discovery: Large-scale clinical trial confirms: short-term fasting is safe, can enhance anti-tumor immunity
Time of Update: 2022-03-04
Cancer Discovery Cancer Discovery Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in cancer patientsCONCLUSIONS: Fasting involving short-term, severe caloric restriction is safe and feasible in cancer patients receiving standard care and results in lower blood glucose and growth factor concentrations, decreased peripheral blood immunosuppressive cells, and intratumoral T cell infiltration.
-
Transl Lung Cancer Res: The relationship between PD-L1 expression level and maintenance treatment efficacy of durvalumab in patients with stage III NSCLC
Time of Update: 2022-03-04
Lung cancerNSCLCThe study included patients with stage III NSCLC who received durvalumab maintenance therapy from July 2017 to July 2019 .
The study included patients with stage III NSCLC who received durvalumab maintenance therapy from July 2017 to July 2019 .
-
Transl Lung Cancer Res: Influence of previous thoracic radiotherapy (RT) on the efficacy of anlotinib in patients with recurrent small cell lung cancer (SCLC)
Time of Update: 2022-03-04
Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial ALTER 1202 Shows that anlotinib Extends Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed Small Cell Lung Cancer (SCLC) .
-
Clin Cancer Res: Cabozantinib and Nivolumab in PCI-Refractory Metastatic Urothelial Carcinoma
Time of Update: 2022-03-04
FDAThe aim of this study was to evaluate the efficacy and tolerability of cabozantinib in combination with nivolumab (CaboNivo) in patients with metastatic urothelial carcinoma that has progressed after checkpoint inhibitor therapy .
-
JAMA sub-issue: 2.5 hours of activity per week, the risk of death has dropped by nearly 70%!
Time of Update: 2022-03-04
This study aimed to investigate the independent and joint associations of daily sedentary time and leisure time physical activity with mortality outcomes in cancer survivors .
This study aimed to investigate the independent and joint associations of daily sedentary time and leisure time physical activity with mortality outcomes in cancer survivors .
-
Target Oncol: Evaluating the efficacy of second-line osimertinib therapy in real-world patients who met and did not meet AURA3 study criteria
Time of Update: 2022-03-04
This retrospective study included patients with advanced NSCLC who received osimertinib after first-line therapy and were divided into two groups according to the inclusion criteria of the AURA3 trial .
-
IJMI: The screening accuracy rate is as high as 92.1%!
Time of Update: 2022-03-04
A research team from the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences proposed a non-invasive screening method for cervical lesions based on transmembrane fusion cytology, HPV detection and colposcopy image examination results.
-
iRECIST Criteria for Evaluation of the Response of Immunotherapy in Solid Tumors
Time of Update: 2022-03-04
(3) Using a single objective standard to reflect complex lesions, ignoring changes in tumor burden, which often best reflects the quality of life and survival time of patients .
-
NEJM: Darolutamide in combination with androgen deprivation therapy-docetaxel in metastatic hormone-sensitive prostate cancer
Time of Update: 2022-03-04
However, it is unclear whether the combination of darolutamide, androgen deprivation therapy, and docetaxel improves survival in patients with metastatic hormone-sensitive prostate cancer .
-
Clin Cancer Res: SD-101 in combination with pembrolizumab in recurrent/metastatic squamous cell carcinoma
Time of Update: 2022-03-04
Median overall survival was approximately 10 months with platinum, 5-fluorouracil, and cetuximab as standard first-line therapy, but more than 80% of patients experienced grade 3 or higher treatment-related adverse events .
-
Cell Reports: NAD+ Enhances Cancer Immunotherapy Efficacy
Time of Update: 2022-03-04
On August 10, 2021, Professor Gao Feng Fan and Professor Haopeng Wang from the School of Life Science and Technology, ShanghaiTech University, as co-corresponding authors, published an online article in the journal Cell Reports entitled: NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT Research paper on transcription in tumor-infiltrated T cells .
-
Ann Oncol: Second-line Osimertinib (osimertinib) combined with bevacizumab does not significantly improve the prognosis of patients with T790M mutation in EGFR-mutant advanced NSCLC
Time of Update: 2022-03-04
Therefore, the results of a phase II study, BOOSTER, were published in Annals of Oncology, evaluating second-line Osimertinib (osimertinib) combined with bevacizumab versus Osimertinib (osimertinib) monotherapy in patients with EGFR T790M-mutated advanced NSCLC.
-
Professor Shi Hanping was elected as the chairman of the Cancer Nutrition Professional Committee of the Chinese Anti-Cancer Association
Time of Update: 2022-03-02
Shi Hanping, Director of the Second Ward of Gastrointestinal Surgery, Beijing Shijitan Hospital, Director of the Department of Clinical Nutrition, and Director of the Department of Oncology, Capital Medical University .
-
5 medical companies received 100 million yuan in financing within 3 days, and oncology and brain science attracted capital attention
Time of Update: 2022-03-02
, a domestic medical device company in the field of minimally invasive orthopaedics, announced that it formally introduced Decheng Capital to complete a new round of investment of 100 million yuan .
-
What's wrong with lymphoma?
Time of Update: 2022-03-02
Will my life with cancer never return to the past?(Reyizha Liu Weiping, Department of Lymphoma, Peking University Cancer Hospital)In the 2022 Beijing Winter Olympics, Canadian star Max Parrot won the men's snowboard championship, but who would have thought that he was a lymphoma patient at the age of 27 .
-
2022 ASCO GI ｜ Voice of China: REAL study results show that robotic surgery can improve surgical injury in patients with low and middle rectal cancer
Time of Update: 2022-02-21
This study was a multicenter randomized controlled clinical trial comparing the effects of robotic surgery and traditional laparoscopic surgery on surgical quality and long-term oncological outcomes in patients with low- and mid-range rectal cancer .
-
The National Health Commission authoritatively released: the 2022 edition of the "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer", a comprehensive interpretation of the treatment update!
Time of Update: 2022-02-21
(6) Systemic chemotherapy FOLFOX4 regimen is approved in China for first-line treatment of locally advanced and metastatic liver cancer not suitable for surgical resection or local therapy (evidence level 2, recommendation A) .
